By Application
Hot products 
-
Rabbit Anti-ENO2 Recombinant Antibody (BA0013) (CBMAB-0272CQ)
-
Mouse Anti-A2M Recombinant Antibody (V2-178822) (CBMAB-A0036-YC)
-
Mouse Anti-APCS Recombinant Antibody (CBYC-A663) (CBMAB-A3054-YC)
-
Mouse Anti-CTNND1 Recombinant Antibody (CBFYC-2414) (CBMAB-C2487-FY)
-
Mouse Anti-AFDN Recombinant Antibody (V2-58751) (CBMAB-L0408-YJ)
-
Mouse Anti-2C TCR Recombinant Antibody (V2-1556) (CBMAB-0951-LY)
-
Mouse Anti-AMH Recombinant Antibody (5/6) (CBMAB-A2527-YC)
-
Mouse Anti-APOE Recombinant Antibody (A1) (CBMAB-0078CQ)
-
Mouse Anti-GPR34 Recombinant Antibody (CBFYH-0457) (CBMAB-H1331-FY)
-
Mouse Anti-CALR Recombinant Antibody (CBFYC-0763) (CBMAB-C0818-FY)
-
Mouse Anti-GIPC2 Recombinant Antibody (10) (CBMAB-G0476-LY)
-
Mouse Anti-DMD Recombinant Antibody (D1190) (CBMAB-D1190-YC)
-
Mouse Anti-APP Recombinant Antibody (DE2B4) (CBMAB-1122-CN)
-
Mouse Anti-FPR2 Recombinant Antibody (1D6) (CBMAB-F2628-CQ)
-
Mouse Anti-CD24 Recombinant Antibody (2Q1282) (CBMAB-C1624-CN)
-
Mouse Anti-AKT1 (Phosphorylated S473) Recombinant Antibody (V2-505430) (PTM-CBMAB-0067LY)
-
Mouse Anti-ABL2 Recombinant Antibody (V2-179121) (CBMAB-A0364-YC)
-
Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
-
Mouse Anti-AK4 Recombinant Antibody (V2-180419) (CBMAB-A1891-YC)
-
Mouse Anti-DES Monoclonal Antibody (440) (CBMAB-AP1857LY)
Skin Cancer (SCC)
Fig.1 Squamous cell skin cancer
Squamous-cell skin cancer, also named as cutaneous squamous-cell carcinoma (cSCC), is one of the typical types of skin cancer along with melanoma and basal cell cancer. Normally, it presents as a hard lump with a scaly top but can also deteriorate into an ulcer. Onset is often several months. Squamous-cell skin cancer is more likely to spread to distant areas comparing with basal cell cancer. The greatest risk factor is the high total exposure to ultraviolet radiation from the sun. Squamous cell cancers happening in the ears and lip have high possibilities of local recurrence and distant metastasis (about 20–50%). SCCs represent around 20% of the non-melanoma skin cancers, but on account of their more obvious nature and growth rates, they stands for 90% of all head and neck cancers that are primarily presented. CD10, as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma, has been studied.
Loading...
Compare
